[1]曾小莲,吴艳花,刘荣昌.经基因重组人生长激素治疗不同骨龄的特发性身材矮小儿童的临床研究[J].医学信息,2023,36(20):125-128.[doi:10.3969/j.issn.1006-1959.2023.20.024]
　ZENG Xiao-lian,WU Yan-hua,LIU Rong-chang.Clinical Study of Recombinant Human Growth Hormone in the Treatment of Idiopathic Short Stature Children with Different Bone Ages[J].Journal of Medical Information,2023,36(20):125-128.[doi:10.3969/j.issn.1006-1959.2023.20.024]
点击复制

经基因重组人生长激素治疗不同骨龄的特发性身材矮小儿童的临床研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年20期
页码:
125-128
栏目:
论著
出版日期:
2023-10-15

文章信息/Info

Title:
Clinical Study of Recombinant Human Growth Hormone in the Treatment of Idiopathic Short Stature Children with Different Bone Ages
文章编号:
1006-1959（2023）20-0125-04
作者:
曾小莲; 吴艳花; 刘荣昌
（上犹县人民医院儿科，江西 上犹 341200）
Author(s):
ZENG Xiao-lian; WU Yan-hua; LIU Rong-chang
(Department of Pediatrics,People’s Hospital of Shangyou County,Shangyou 341200,Jiangxi,China)
关键词:
经基因重组人生长激素; 骨龄; 特发性身材矮小
Keywords:
Recombinant human growth hormone; Bone age; Idiopathic short stature
分类号:
R729
DOI:
10.3969/j.issn.1006-1959.2023.20.024
文献标志码:
A
摘要:
目的 研究经基因重组人生长激素治疗不同骨龄的特发性身材矮小儿童的临床疗效。方法 选取2021年8月-2022年10月在我院诊治的60例特发性身材矮小儿童为研究对象，依据骨龄分为对照1组（5~8岁，n=30）和对照2组（9~12岁，n=30），均给予基因重组人生长激素治疗，比较两组临床疗效、生长相关指标（身高、胰岛素样生长因子-1）、骨代谢指标（骨密度、骨钙素）及不良反应发生率。结果 对照1组治疗总有效率为93.33%，高于对照2组的83.33%（P＜0.05）；两组治疗后身高、胰岛素样生长因子-1水平均高于治疗前，且对照1组高于对照2组（P＜0.05）；两组治疗后骨密度、骨钙素水平均高于治疗前，且对照1组高于对照2组（P＜0.05）；对照1组不良反应发生率为6.67%，低于对照2组的16.67%（P＜0.05）。结论 经基因重组人生长激素治疗不同骨龄的特发性身材矮小儿童临床疗效存在差异，相对而言低骨龄（5~8岁）患儿的治疗效果更为突出，身高、骨代谢指标均改善，且不良反应发生率低，值得临床应用。
Abstract:
Objective To study the clinical efficacy of recombinant human growth hormone in the treatment of idiopathic short stature children with different bone ages.Methods Sixty children with idiopathic short stature diagnosed and treated in our hospital from August 2021 to October 2022 were selected as the research objects. According to bone age, they were divided into control group 1 (5-8 years old, n=30) and control group 2 (9-12 years old, n=30). Both groups were treated with recombinant human growth hormone. The clinical efficacy, growth-related indicators (height, insulin-like growth factor-1), bone metabolism indicators (bone mineral density, osteocalcin) and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the control group 1 was 93.33%, which was higher than 83.33% in the control group 2 (P<0.05). After treatment, the height and insulin-like growth factor-1 levels in the two groups were higher than those before treatment, and those in the control group 1 were higher than those in the control group 2 (P<0.05). After treatment, the bone mineral density and osteocalcin levels in the two groups were higher than those before treatment, and those in the control group 1 were higher than those in the control group 2 (P<0.05). The incidence of adverse reactions in the control group 1 was 6.67%, which was lower than 16.67% in the control group 2 (P<0.05).Conclusion The clinical efficacy of recombinant human growth hormone in the treatment of idiopathic short stature children with different bone ages is different. Relatively speaking, the treatment effect of children (5-8 years old) with low bone age is more prominent, and the height and bone metabolism indexes are improved, and the incidence of adverse reactions is low, which is worthy of clinical application.

参考文献/References:

[1]刘芳,陈俐君,晏世玲.重组人生长激素治疗青春期早期特发性矮小症对骨代谢的影响[J].儿科药学杂志,2019,25(6):30-33.[2]沈琳娜,夏欢,宋月娟.重组人生长激素治疗特发性矮小症儿童的疗效观察及对胰岛素样生长因子的影响[J].贵州医药,2017,41(12):1262-1264.[3]王昭睿,郝萌萌.重组人生长激素治疗儿童特发性矮小39 例分析[J].中国儿童保健杂志,2017,25(4):423-424.[4]郝利苹,刘戈力,杨箐岩,等.重组人生长激素治疗儿童特发性矮小症的疗效及对血清Ghrelin和IGF-1水平的影响[J].现代生物医学进展,2018,18(20):64-67,88.[5]孟晓波,朱华,于少飞,等.重组人生长激素治疗特发性矮小症患儿疗效及安全性研究[J].检验医学与临床,2017,14(18):2737-2739.[6]刘建平,黄路圣,叶林华.胰岛素样生长因子-1水平监测在重组人生长激素治疗特发性矮小症中的临床意义[J].现代中西医结合杂志,2017,26(32):3568-3571.[7]陈立娟,李斌,刘霞.不同剂量生长激素对特发性矮小症患儿身高、生长速率及骨龄的影响[J].中国优生与遗传杂志,2019,27(11):1379-1380.[8]赵强,李志洁.重组人生长激素治疗儿童生长激素缺乏症和特发性矮小症45例疗效观察[J].中国妇幼保健,2018,31(6):1300-1302．[9]何英,柳开典,袁作芬,等.重组人生长激素对GHD和ISS患儿的临床影响[J].中国妇幼健康研究,2017,28(10):1281-1283.[10]张本金,吕有道,邓春晖.不同剂量重组人生长激素.治疗青春期前ISS患者的临床疗效分析[J].重庆医学,2018,45(6):813-815.[11]Saenger P.Ten years of biosimilar recombinant human growth hormone in Europe[J].Drug Design Development & Therapy,2017,11:1505-1507.[12]李想,乐原.基因重组人生长激素治疗特发性矮小症患儿的临床疗效及安全性研究[J].锦州医科大学学报,2018,39(2):20-22.[13]Peng P,Ma C,Wan S,et al.Inhibition of p53 relieves insulin resistance in fetal growth restriction mice with catch-up growth via activating IGFBP3/IGF-1/IRS-1/Akt signaling pathway[J].Journal of Nanoscience & Nanotechnology,2018,18(6):3925-3935.[14]陈立黎,朱高慧,熊丰,等.重组人生长激素治疗儿童特发性矮小症远期疗效分析[J].儿科药学杂志,2018,24(6):13-16.[15]郭艳艳,蒋成霞,姚兰,等.不同剂量重组人生长激素治疗特发性矮小症患儿身高、体 重 以及血清IGF-1和IGFBP-3表达的影响[J].解放军医药杂志,2020,32(3):44-47.[16]陈秀芳,冯海英,蔡玲芳,等.重组人生长激素联合心理干预治疗特发性矮小症效果评价[J].中国学校卫生,2018,39(8):1210-1212.[17]郑贺丽,王伟,姜书琴,等.重组人生长激素干预对特发性矮小患儿颅面部生长发育的影响[J].中华实用儿科临床杂志,2019,34(10):785-787.[18]杨丽萍,宇根于,谢宇飞.重组人生长激素在儿童生长激素缺乏症和特发性矮小症治疗中的临床应用[J].中国药物与临床,2021,21(11):1849-1851.[19]郝亚华,梁英,张凡.重组人生长激素治疗特发性矮小症患儿的临床疗效分析[J].中国药物与临床,2019,19(3):418-419.[20]杨志敏,鞠海超.重组人生长激素对特发性矮小症患儿身高及血清胰岛素样生长因子1的影响[J].中国基层医药,2020,27(19):2334-2338.

相似文献/References:

[1]李冰一,张丽华,宋玲玲,等.成都市某儿童健康管理中心体检儿童X线骨龄检测分析[J].医学信息,2022,35(15):138.[doi:10.3969/j.issn.1006-1959.2022.15.032]
　LI Bing-yi,ZHANG Li-hua,SONG Ling-ling,et al.Analysis of X-ray Skeletal Age of Physical Examination Children in a Child Health Management Center in Chengdu[J].Journal of Medical Information,2022,35(20):138.[doi:10.3969/j.issn.1006-1959.2022.15.032]
[2]陈永花,王春林.肥胖儿童骨龄提前的相关因素分析[J].医学信息,2022,35(07):73.[doi:10.3969/j.issn.1006-1959.2022.07.018]
　CHEN Yong-hua,WANG Chun-lin.Analysis of Related Factors of Early Bone Age in Obese Children[J].Journal of Medical Information,2022,35(20):73.[doi:10.3969/j.issn.1006-1959.2022.07.018]

更新日期/Last Update: 1900-01-01